NR-50843人类早期恢复期血浆W23651631115700抗寨卡病毒(多克隆抗血清）

NR-50843?? Human Early Convalescent Plasma W23651631115700 to Zika Virus(Polyclonal Antiserum)|Zika virus|Human Early Convalescent Plasma W23651631115700 to Zika Virus|-80°C or colder|MP BuschAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Human Early Convalescent Plasma W23651631115700 to Zika Virus, NR-50843.” All oral presentations or written publications concerning the use of this material must also include the following acknowledgement of the Contributor: “This manuscript was prepared using samples provided by Blood Systems Research Institute (BSRI) from studies funded in whole or in part by Contract No. HHSN268201100001I from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health; Roche Molecular Systems, Inc.; and Contract No. HHSO100201600010C from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority. The content is solely the responsibility of the authors and does not necessarily represent the official views of BSRI, the NHLBI, or the National Institutes of Health."|

Quantity limit per order for this item is 1.  This item can be ordered twice a year.  Orders over this limit will be sent to NIAID for approval before shipment.

NR-50843 is early convalescent plasma collected on June 15, 2016, from a human subject with a confirmed Zika virus (ZIKV) infection and prior dengue virus (DENV) exposure. The sample is positive for ZIKV RNA, positive for anti-ZIKV IgM, positive for anti-ZIKV IgG, and positive for anti-DENV IgG.  

Each vial contains approximately 0.5 mL of plasma.